Nivolumab Fails to Outperform Durvalumab in Stage III Lung Cancer Trial
A phase 3 trial finds nivolumab-based regimens offer no survival advantage over durvalumab for unresectable stage III NSCLC.
512 articles in this topic
A phase 3 trial finds nivolumab-based regimens offer no survival advantage over durvalumab for unresectable stage III NSCLC.
A newly identified enzyme links lactate metabolism to liver cancer progression, and a natural compound delivered via nanoparticles shows striking anti-tumor results.
Cambridge scientists engineer a nanoprobe that detects therapy-induced senescence non-invasively through a simple urine colorimetric test.
Scientists found drugs that kill senescent 'zombie cells' by blocking their key survival protein, shrinking tumors in mice.
The FDA approved zenocutuzumab-zbco for adults with advanced, unresectable, or metastatic cholangiocarcinoma, a rare and aggressive bile duct cancer with limited treatment options.
Phase 1 trial of acapatamab, a PSMA-targeting bispecific T-cell engager, enrolls 212 men with metastatic castration-resistant prostate cancer.
A large retrospective study tests whether AI-enhanced ECGs can flag cardiac risk before chemotherapy, potentially protecting cancer patients from heart damage.
A completed pilot trial tested physical therapy and progressive muscle relaxation to preserve function and mood in older adults with advanced lung cancer.
A large French cohort study reveals conjugated bile acids raise breast cancer risk while vitamin K intake may be protective via metabolic pathways.
A Dana-Farber review maps the path for personalized cancer vaccines โ pinpointing which tumors, timing, and combination strategies will matter most.
Peter Attia breaks down why colorectal cancer is one of the most preventable cancers and how to build a personalized screening strategy.
Path2Space uses deep learning to infer spatial gene expression from standard tissue slides, enabling low-cost breast cancer biomarker discovery at scale.